Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Genetic variation determines VEGF-A plasma levels in cancer patients.

Innocenti F, Jiang C, Sibley AB, Etheridge AS, Hatch AJ, Denning S, Niedzwiecki D, Shterev ID, Lin J, Furukawa Y, Kubo M, Kindler HL, Auman JT, Venook AP, Hurwitz HI, McLeod HL, Ratain MJ, Gordan R, Nixon AB, Owzar K.

Sci Rep. 2018 Nov 5;8(1):16332. doi: 10.1038/s41598-018-34506-4.

2.

Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105.

Liu Y, Starr MD, Brady JC, Rushing C, Pang H, Adams B, Alvarez D, Theuer CP, Hurwitz HI, Nixon AB.

Mol Cancer Ther. 2018 Oct;17(10):2248-2256. doi: 10.1158/1535-7163.MCT-17-0916. Epub 2018 Jul 11.

PMID:
29997150
3.

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L.

Ann Oncol. 2018 May 1;29(5):1108-1119. doi: 10.1093/annonc/mdy100.

4.

A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer.

Vlahovic G, Meadows KL, Hatch AJ, Jia J, Nixon AB, Uronis HE, Morse MA, Selim MA, Crawford J, Riedel RF, Zafar SY, Howard LA, O'Neill M, Meadows JJ, Haley ST, Arrowood CC, Rushing C, Pang H, Hurwitz HI.

Oncologist. 2018 Jul;23(7):782-790. doi: 10.1634/theoncologist.2016-0377. Epub 2018 Mar 23.

PMID:
29572245
5.

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer.

Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall JL, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA Jr.

Clin Cancer Res. 2018 Jan 15;24(2):316-325. doi: 10.1158/1078-0432.CCR-17-1558. Epub 2017 Oct 30.

PMID:
29084918
6.

Pilot Evaluation of Angiogenesis Signaling Factor Response after Transcatheter Arterial Embolization for Hepatocellular Carcinoma.

Ronald J, Nixon AB, Marin D, Gupta RT, Janas G, Chen W, Suhocki PV, Pabon-Ramos W, Sopko DR, Starr MD, Brady JC, Hurwitz HI, Kim CY.

Radiology. 2017 Oct;285(1):311-318. doi: 10.1148/radiol.2017162555. Epub 2017 Aug 8.

PMID:
28787261
7.

Phase I study of pazopanib plus TH-302 in advanced solid tumors.

Riedel RF, Meadows KL, Lee PH, Morse MA, Uronis HE, Blobe GC, George DJ, Crawford J, Niedzwiecki D, Rushing CN, Arrowood CC, Hurwitz HI.

Cancer Chemother Pharmacol. 2017 Mar;79(3):611-619. doi: 10.1007/s00280-017-3256-2. Epub 2017 Feb 25.

PMID:
28238078
8.

Percutaneous biliary drainage catheter insertion in patients with extensive hepatic metastatic tumor burden.

Langman EL, Suhocki PV, Hurwitz HI, Morse MA, Burbridge RA, Smith TP, Kim CY.

J Gastrointest Oncol. 2016 Dec;7(6):875-881. doi: 10.21037/jgo.2016.06.13.

9.

Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Hatch AJ, Sibley AB, Starr MD, Brady JC, Jiang C, Jia J, Bowers DL, Pang H, Owzar K, Niedzwiecki D, Innocenti F, Venook AP, Hurwitz HI, Nixon AB; Alliance for Clinical Trials in Oncology.

Cancer Med. 2016 Sep;5(9):2249-60. doi: 10.1002/cam4.806. Epub 2016 Jul 27.

10.

HER2 testing in metastatic colorectal cancer: ready for prime time?

Hurwitz HI.

Clin Adv Hematol Oncol. 2016 Apr;14(4):235-7. No abstract available.

PMID:
27166605
11.

Development of a Novel c-MET-Based CTC Detection Platform.

Zhang T, Boominathan R, Foulk B, Rao C, Kemeny G, Strickler JH, Abbruzzese JL, Harrison MR, Hsu DS, Healy P, Li J, Pi C, Prendergast KM, Hobbs C, Gemberling S, George DJ, Hurwitz HI, Connelly M, Garcia-Blanco MA, Armstrong AJ.

Mol Cancer Res. 2016 Jun;14(6):539-47. doi: 10.1158/1541-7786.MCR-16-0011. Epub 2016 Mar 7.

12.

Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed.

Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS.

J Clin Oncol. 2015 Dec 1;33(34):4039-47. doi: 10.1200/JCO.2015.61.4578. Epub 2015 Sep 8.

13.

Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.

Hatch AJ, Clarke JM, Nixon AB, Hurwitz HI.

Cancer J. 2015 Jul-Aug;21(4):322-6. doi: 10.1097/PPO.0000000000000129. Review.

PMID:
26222085
14.

Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing.

Jia J, Dellinger AE, Weiss ES, Bulusu A, Rushing C, Li H, Howard LA, Kaplan N, Pang H, Hurwitz HI, Nixon AB.

Clin Cancer Res. 2015 Aug 1;21(15):3442-52. doi: 10.1158/1078-0432.CCR-14-2819. Epub 2015 Apr 15.

15.

Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.

Chiorean EG, Hurwitz HI, Cohen RB, Schwartz JD, Dalal RP, Fox FE, Gao L, Sweeney CJ.

Ann Oncol. 2015 Jun;26(6):1230-7. doi: 10.1093/annonc/mdv144. Epub 2015 Mar 18.

PMID:
25787923
16.

Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study.

Hurwitz HI, Smith DC, Pitot HC, Brill JM, Chugh R, Rouits E, Rubin J, Strickler J, Vuagniaux G, Sorensen JM, Zanna C.

Cancer Chemother Pharmacol. 2015 Apr;75(4):851-9. doi: 10.1007/s00280-015-2709-8. Epub 2015 Feb 27.

17.

Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Loupakis F, Yang D, Yau L, Feng S, Cremolini C, Zhang W, Maus MK, Antoniotti C, Langer C, Scherer SJ, Müller T, Hurwitz HI, Saltz L, Falcone A, Lenz HJ.

J Natl Cancer Inst. 2015 Feb 24;107(3). pii: dju427. doi: 10.1093/jnci/dju427. Print 2015 Mar.

18.

Biomarker signatures correlate with clinical outcome in refractory metastatic colorectal cancer patients receiving bevacizumab and everolimus.

Liu Y, Starr MD, Brady JC, Rushing C, Bulusu A, Pang H, Honeycutt W, Amara A, Altomare I, Uronis HE, Hurwitz HI, Nixon AB.

Mol Cancer Ther. 2015 Apr;14(4):1048-56. doi: 10.1158/1535-7163.MCT-14-0923-T. Epub 2015 Feb 18.

19.

Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.

Reichardt P, Kang YK, Rutkowski P, Schuette J, Rosen LS, Seddon B, Yalcin S, Gelderblom H, Williams CC Jr, Fumagalli E, Biasco G, Hurwitz HI, Kaiser PE, Fly K, Matczak E, Chen L, Lechuga MJ, Demetri GD.

Cancer. 2015 May 1;121(9):1405-13. doi: 10.1002/cncr.29220. Epub 2015 Jan 13.

20.

A leave-one-out cross-validation SAS macro for the identification of markers associated with survival.

Rushing C, Bulusu A, Hurwitz HI, Nixon AB, Pang H.

Comput Biol Med. 2015 Feb;57:123-9. doi: 10.1016/j.compbiomed.2014.11.015. Epub 2014 Dec 9.

21.

A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.

Uronis HE, Jia J, Bendell JC, Howard L, Ready NA, Lee PH, Starr MD, Dellinger A, Pang H, Nixon AB, Hurwitz HI.

Cancer Chemother Pharmacol. 2015 Feb;75(2):343-52. doi: 10.1007/s00280-014-2647-x. Epub 2014 Dec 20.

PMID:
25527204
22.

Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance).

Cushman SM, Jiang C, Hatch AJ, Shterev I, Sibley AB, Niedzwiecki D, Venook AP, Owzar K, Hurwitz HI, Nixon AB.

Clin Cancer Res. 2015 Mar 1;21(5):1078-86. doi: 10.1158/1078-0432.CCR-14-2313. Epub 2014 Dec 17.

23.

Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.

Meadows KL, Rushing C, Honeycutt W, Latta K, Howard L, Arrowood CA, Niedzwiecki D, Hurwitz HI.

Support Care Cancer. 2015 May;23(5):1311-9. doi: 10.1007/s00520-014-2465-z. Epub 2014 Oct 24.

24.

The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer.

Secord AA, Nixon AB, Hurwitz HI.

Gynecol Oncol. 2014 Nov;135(2):349-58. doi: 10.1016/j.ygyno.2014.08.033. Epub 2014 Aug 30. Review.

PMID:
25178997
25.

Understanding the mechanisms of action of antiangiogenic agents in metastatic colorectal cancer: a clinician's perspective.

Clarke JM, Hurwitz HI, Rangwala F.

Cancer Treat Rev. 2014 Oct;40(9):1065-72. doi: 10.1016/j.ctrv.2014.07.001. Epub 2014 Jul 11. Review.

PMID:
25047778
26.

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Liu Y, Tian H, Blobe GC, Theuer CP, Hurwitz HI, Nixon AB.

Invest New Drugs. 2014 Oct;32(5):851-9. doi: 10.1007/s10637-014-0129-y. Epub 2014 Jul 5.

27.

A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.

Cleary JM, Lima CM, Hurwitz HI, Montero AJ, Franklin C, Yang J, Graham A, Busman T, Mabry M, Holen K, Shapiro GI, Uronis H.

Invest New Drugs. 2014 Oct;32(5):937-45. doi: 10.1007/s10637-014-0110-9. Epub 2014 Jun 11.

PMID:
24916770
28.

Metastatic ampullary adenocarcinoma presenting as a hydrocele: a case report.

Lane WO, Bentley RC, Hurwitz HI, Howard LA, Polascik TJ, Anderson MR, Blazer DG.

JOP. 2014 May 27;15(3):266-8. doi: 10.6092/1590-8577/2407.

29.

Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.

Grothey A, Flick ED, Cohn AL, Bekaii-Saab TS, Bendell JC, Kozloff M, Roach N, Mun Y, Fish S, Hurwitz HI.

Pharmacoepidemiol Drug Saf. 2014 Jul;23(7):726-34. doi: 10.1002/pds.3633. Epub 2014 May 16.

PMID:
24830357
30.

Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.

Rangwala F, Bendell JC, Kozloff MF, Arrowood CC, Dellinger A, Meadows J, Tourt-Uhlig S, Murphy J, Meadows KL, Starr A, Broderick S, Brady JC, Cushman SM, Morse MA, Uronis HE, Hsu SD, Zafar SY, Wallace J, Starodub AN, Strickler JH, Pang H, Nixon AB, Hurwitz HI.

Invest New Drugs. 2014 Aug;32(4):700-9. doi: 10.1007/s10637-014-0089-2. Epub 2014 Apr 9.

31.

Safety and effectiveness of bevacizumab treatment for metastatic colorectal cancer: final results from the Avastin(®) Registry - Investigation of Effectiveness and Safety (ARIES) observational cohort study.

Hurwitz HI, Bekaii-Saab TS, Bendell JC, Cohn AL, Kozloff M, Roach N, Mun Y, Fish S, Flick ED, Grothey A; ARIES Study Investigators.

Clin Oncol (R Coll Radiol). 2014 Jun;26(6):323-32. doi: 10.1016/j.clon.2014.03.001. Epub 2014 Mar 28.

PMID:
24686090
32.

A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.

Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ.

Clin Genitourin Cancer. 2014 Aug;12(4):241-50. doi: 10.1016/j.clgc.2013.11.020. Epub 2013 Nov 14.

33.

Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.

Liu Y, Starr MD, Brady JC, Dellinger A, Pang H, Adams B, Theuer CP, Lee NY, Hurwitz HI, Nixon AB.

Cancer Med. 2014 Jun;3(3):580-91. doi: 10.1002/cam4.207. Epub 2014 Feb 14.

34.

Palliative treatment of metastatic colorectal cancer: what is the optimal approach?

Strickler JH, Hurwitz HI.

Curr Oncol Rep. 2014;16(1):363. doi: 10.1007/s11912-013-0363-z. Review.

PMID:
24293074
35.

Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.

Strickler JH, McCall S, Nixon AB, Brady JC, Pang H, Rushing C, Cohn A, Starodub A, Arrowood C, Haley S, Meadows KL, Morse MA, Uronis HE, Blobe GC, Hsu SD, Zafar SY, Hurwitz HI.

Invest New Drugs. 2014 Apr;32(2):330-9. doi: 10.1007/s10637-013-0042-9. Epub 2013 Nov 1.

36.

Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.

Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S.

Clin Cancer Res. 2014 Jan 15;20(2):480-9. doi: 10.1158/1078-0432.CCR-13-1840. Epub 2013 Oct 30.

37.

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI; Alliance for Clinical Trials In Oncology.

Clin Cancer Res. 2013 Dec 15;19(24):6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4.

38.

Understanding and targeting resistance to anti-angiogenic therapies.

Clarke JM, Hurwitz HI.

J Gastrointest Oncol. 2013 Sep;4(3):253-63. doi: 10.3978/j.issn.2078-6891.2013.036.

39.

A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.

Uronis HE, Cushman SM, Bendell JC, Blobe GC, Morse MA, Nixon AB, Dellinger A, Starr MD, Li H, Meadows K, Gockerman J, Pang H, Hurwitz HI.

Cancer Med. 2013 Jun;2(3):316-24. doi: 10.1002/cam4.65. Epub 2013 Mar 21.

40.

Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.

Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J.

Oncologist. 2013;18(9):1004-12. doi: 10.1634/theoncologist.2013-0107. Epub 2013 Jul 23.

41.

Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Clarke JM, Hurwitz HI.

Expert Opin Biol Ther. 2013 Aug;13(8):1187-96. doi: 10.1517/14712598.2013.810717. Epub 2013 Jun 26. Review.

42.

The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.

Rosen LS, Lipton L, Price TJ, Belman ND, Boccia RV, Hurwitz HI, Stephenson JJ Jr, Wirth LJ, McCoy S, Hei YJ, Hsu CP, Tebbutt NC.

BMC Cancer. 2013 May 16;13:242. doi: 10.1186/1471-2407-13-242.

43.

Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.

Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB.

Cancer Med. 2013 Apr;2(2):234-42. doi: 10.1002/cam4.71. Epub 2013 Mar 6.

44.

A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.

Uronis HE, Bendell JC, Altomare I, Blobe GC, Hsu SD, Morse MA, Pang H, Zafar SY, Conkling P, Favaro J, Arrowood CC, Cushman SM, Meadows KL, Brady JC, Nixon AB, Hurwitz HI.

Oncologist. 2013;18(3):271-2. doi: 10.1634/theoncologist.2012-0404. Epub 2013 Mar 13.

45.

Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.

Hurwitz HI, Douglas PS, Middleton JP, Sledge GW, Johnson DH, Reardon DA, Chen D, Rosen O.

Oncologist. 2013;18(3):273-80. doi: 10.1634/theoncologist.2012-0339. Epub 2013 Mar 13.

46.

Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.

Jia J, Starodub A, Cushman I, Liu Y, Marshall DJ, Hurwitz HI, Nixon AB.

Anticancer Drugs. 2013 Mar;24(3):237-50. doi: 10.1097/CAD.0b013e32835d29fd.

47.

Ziv-aflibercept: binding to more than VEGF-A--does more matter?

Clarke JM, Hurwitz HI.

Nat Rev Clin Oncol. 2013 Jan;10(1):10-1. doi: 10.1038/nrclinonc.2012.197. Epub 2012 Nov 13.

PMID:
23149898
48.

Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?

Weinfurt KP, Seils DM, Lin L, Sulmasy DP, Astrow AB, Hurwitz HI, Cohen RB, Meropol NJ.

J Clin Oncol. 2012 Dec 10;30(35):4396-400. doi: 10.1200/JCO.2011.40.6587. Epub 2012 Oct 22.

49.

Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.

de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI.

Invest New Drugs. 2013 Jun;31(3):751-9. doi: 10.1007/s10637-012-9885-8. Epub 2012 Oct 6.

PMID:
23054212
50.

Anti-VEGF therapies in the clinic.

Meadows KL, Hurwitz HI.

Cold Spring Harb Perspect Med. 2012 Oct 1;2(10). pii: a006577. doi: 10.1101/cshperspect.a006577. Review.

Supplemental Content

Loading ...
Support Center